Drug Discovery Processes

Video: PerkinElmer signals lead discovery

3 January 2018 | By PerkinElmer

Quickly gain new insights into chemical and biomolecular research data. Featuring guided search and analysis workflows and dynamic data visualisations.

Scientific poster: Developing protein: Protein Interaction (PPI) assays with AlphaLISA and LANCE TR-FRET

2 January 2018 | By Catherine Lautenschlager (PerkinElmer), Daniel Cardillo (PerkinElmer), Matthew Reuter (PerkinElmer)

In this scientific poster, PerkinElmer demonstrates the ease and utility of using AlphaLISA® and LANCE® TR-FRET homogenous assay forms for studying PPIs.

Using open science to develop Pediatric Cancer Drugs

2 January 2018 | By Charles River Laboratories

The webinar speakers highlight the collaboration between patient groups, charities, and academia led to the development of inhibitors targeting gliomas.

A2aAR protein holds clues for better drug design

2 January 2018 | By Dr Zara Kassam (Drug Target Review)

Scientists have investigated a key protein used in drug design and discovered dynamic structural features that may lead to new ways to target diseases...

CXCL5 protein found to stimulate tumour growth in prostate cancer

24 November 2017 | By Dr Zara Kassam (Drug Target Review)

Researchers identify a pathway that causes tumour acceleration in metastatic prostate cancer cells...

TTP Labtech Ltd

Declines in plasticity reveal promising targets for Alzheimer’s disease

26 October 2017 | By Dr Zara Kassam (Drug Target Review)

Brain changes linked to memory loss may provide a new focus for exploring ways to treat or prevent dementia...

Key psychiatric drug target comes into focus

20 October 2017 | By Dr Zara Kassam (Drug Target Review)

Researchers have reported a major step forward towards designing more powerful psychiatric drugs with fewer side effects...

Scientists develop broad-spectrum inhibitors of influenza virus

29 September 2017 | By Dr Zara Kassam (Drug Target Review)

Scientists have developed broad-spectrum inhibitors of the influenza virus using artificial peptide molecules...

Integrated drug discovery panel – your questions answered!

28 September 2017 | By Charles River

During this peer panel discussion, team members from Charles River discussed their views and strategies on Drug Discovery...

Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets

28 September 2017 | By Dr Zara Kassam (Drug Target Review)

Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer...

Streamlined process opens drug development to a new class of steroids

26 September 2017 | By Dr Zara Kassam (Drug Target Review)

Researchers have developed a technique to produce synthetic steroids that could pave the way for a cascade of new drug discoveries...

Potential therapeutic protein inhibitors for Chagas disease

26 September 2017 | By Dr Zara Kassam (Drug Target Review)

Researchers have used a multi-modal integrated approach to develop potential new anti-Chagas therapies...

Webinar: Phenotypic assays for CNS disease drug discovery

21 September 2017 | By Charles River Laboratories

In this webinar, we highlight in vitro models and phenotypic assays to discover and validate novel targets and promising lead molecules...

Application note: Application of MultiCyt QBeads for high throughput cytokine profiling in human peripheral blood mononuclear cells

18 September 2017 | By Kim Luu (IntelliCyt Corporation), Robbie Narang (IntelliCyt Corporation), Zhaoping Liu (IntelliCyt Corporation)

In this application note IntelliCyt Corporation report on the development and validation of their family of MultiCyt QBeads for the detection of cytokines in a high-throughput screening application on the iQue Screener...